share_log

Regeneron Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director RYAN ARTHUR F

Regeneron Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director RYAN ARTHUR F

再生元製藥公司 | 4：持股變動聲明-董事 RYAN ARTHUR F
美股SEC公告 ·  01/07 05:15

Moomoo AI 已提取核心訊息

On January 2, 2025, RYAN ARTHUR F, an executive at Regeneron Pharmaceuticals, was granted 166 shares of Common Stock at $0 per share. This transaction was reported as a direct acquisition under the transaction code 'A', indicating a grant, award, or other acquisition.Following this transaction, RYAN ARTHUR F's direct ownership of Regeneron Pharmaceuticals Common Stock increased to 17,748 shares. The acquisition was completed on the reported date, with no additional transactions mentioned in the filing.
On January 2, 2025, RYAN ARTHUR F, an executive at Regeneron Pharmaceuticals, was granted 166 shares of Common Stock at $0 per share. This transaction was reported as a direct acquisition under the transaction code 'A', indicating a grant, award, or other acquisition.Following this transaction, RYAN ARTHUR F's direct ownership of Regeneron Pharmaceuticals Common Stock increased to 17,748 shares. The acquisition was completed on the reported date, with no additional transactions mentioned in the filing.
2025年1月2日，再生元製藥公司的高管RYAN ARTHUR F獲得了166股普通股，價格爲每股0美元。該交易被報告爲直接收購，交易代碼爲'A'，表示授予、獎勵或其他收購。在此次交易之後，RYAN ARTHUR F對再生元製藥公司的普通股直接持有量增加至17,748股。收購在報告日期完成，申報中沒有提到其他交易。
2025年1月2日，再生元製藥公司的高管RYAN ARTHUR F獲得了166股普通股，價格爲每股0美元。該交易被報告爲直接收購，交易代碼爲'A'，表示授予、獎勵或其他收購。在此次交易之後，RYAN ARTHUR F對再生元製藥公司的普通股直接持有量增加至17,748股。收購在報告日期完成，申報中沒有提到其他交易。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間